Alchemia and AstraZeneca agreed to collaborate in the discovery and potential development of novel small molecules against multiple targets using the former's
Diversity Scanning Array and Versatile Assembly on Stable Templates chemistry technology. AstraZeneca will pay Alchemia an undisclosed upfront fee, research funding, and as much as $240 million in milestone fees plus royalties.

Related Summaries